Unbound MEDLINE

Paroxysmal nocturnal hemoglobinuria following alemtuzumab immunosuppressive therapy for myelodysplastic syndrome and complicated by recurrent life-threatening thrombosis despite anticoagulation: Successful intervention with eculizumab and fondaparinux. Leukemia research [Leuk Res] Journal article

 
TitleParoxysmal nocturnal hemoglobinuria following alemtuzumab immunosuppressive therapy for myelodysplastic syndrome and complicated by recurrent life-threatening thrombosis despite anticoagulation: Successful intervention with eculizumab and fondaparinux.
Author(s)Cheng KL, Brody J, Warshall CE, Sloand EM, Allen SL 
InstitutionMonter Cancer Center, North Shore University Hospital, New York University School of Medicine, Lake Success, NY, USA.
SourceLeuk Res 2009 Oct 14.
LanguageENG
Pub Type(s)LETTER
PubMed ID19836075
  
Advertise on this site.